Voyager Q2 2026 net loss narrows to $24.5 million from $33.4 million
Voyager Therapeutics reported second quarter 2026 results. Collaboration revenue fell to $3.2 million from $5.2 million, while the net loss narrowed to $24.5 million from $33.4 million, and cash, cash equivalents and marketable securities were $148.8 million as of June 30, 2026. The company said the cash is expected to fund planned operations into 2028 and that VY7523 tau PET imaging data and VY1706 dosing are both expected in Q4 2026.
Key points
- Collaboration revenue was $3.2 million, down from $5.2 million a year earlier, mainly due to lower revenue under the Neurocrine collaboration.
- Research and development expenses were $22.0 million, down from $31.3 million, which the company attributed to program and platform prioritization.
- Net loss was $24.5 million, or $0.40 per share, compared with a net loss of $33.4 million, or $0.57 per share, a year earlier.
- Cash and marketable securities were $148.8 million at June 30, 2026, with runway expected into 2028.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.